Exchange: NYSE·Updated 08:03 AM EDT

NVO News

News
all
press releases
Pfizer's Pipeline Strategy Centers on Obesity and Oncology
PFE's pipeline is taking center stage as berobenatide and next-generation oncology drugs aim to drive growth from 2028 and beyond.
Zacks
More News
HIMS Raises 2026 Revenue Outlook as Q2 Sales Rise 38.2% Despite Loss
HIMS raised its 2026 revenue outlook after Q2 sales jumped 38.2%, but margin contraction and an $86.3 million net loss highlighted growth costs.
Zacks
HIMS Stock Kicks Off September In The Red: FDA’s GLP-1 Alert Steals The Spotlight From Australia Expansion
The FDA reported more than 1,700 adverse events involving compounded Semaglutide and Tirzepatide
Stocktwits
GSK Stock Down 14% in Six Months: Time to Buy, Hold or Exit?
GSK's shares are down 14% in six months, but strong Specialty Medicines growth and a robust pipeline may support long-term gains.
Zacks
Eli Lilly CEO Says $25B Deal Spree Is About Building Growth Beyond Obesity Into 2030s — ‘Not All These Bets Will Pay Off’
In an interview with CNBC, CEO David Ricks said the company’s long-term strategy includes making its obesity franchise more durable and investing in technologies to transform the treatment of other diseases.
Stocktwits
LLY's Mounjaro Gets FDA Nod to Cut Cardiovascular Risk in Diabetes
Eli Lilly's Mounjaro wins FDA approval to reduce cardiovascular risk in high-risk T2D patients, expanding its use and commercial opportunity.
Zacks
Can CagriSema Help Novo Nordisk Close the Gap With LLY in Obesity?
NVO's CagriSema is under U.S. regulatory review for obesity, with continued clinical progression to expand use amid increasing competition from LLY.
Zacks
Eli Lilly Strikes $2.9B Deal For Its 13th Acquisition This Year – As Fresh Zepbound Data Impresses
Lilly also announced that combining its inflammation treatment Taltz with Zepbound delivered lasting improvements in adults with psoriasis or psoriatic arthritis who were obese in two late trials.
Stocktwits
Has Novo Nordisk Finally Found the Catalyst That Could Flip the Script on Eli Lilly?
Key PointsNovo Nordisk was first with a GLP-1 weight-loss shot, but lost the lead to Eli Lilly...
Nasdaq News: Markets
Mounjaro Vs Trulicity: Eli Lilly’s New FDA Win Puts Its Blockbuster Weight-Loss Drug In Focus
Mounjaro produced an 8% lower rate of cardiovascular death, heart attack or stroke than Lilly’s diabetes drug Trulicity.
Stocktwits

Advertisement|Remove ads.